John A. Eckman, MD, Patricia M

Slides:

Advertisements

Similar presentations

Buffering airway acid decreases exhaled nitric oxide in asthma Benjamin Gaston, MD, Robin Kelly, RN, Peter Urban, RN, Lei Liu, PhD, Edward M. Henderson,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

Nasal challenge with allergen leads to maxillary sinus inflammation

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy Michael Kulis, PhD, Katie.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine Alina F. Dumitru, MD, Mohamed.

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study John M. Brehm, MD, MPH, Brooke Schuemann, BS,

Is 9 more than 2 also in allergic airway inflammation?

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy Robert A.

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana,

Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,

Basophil FcɛRI histamine release parallels expression of Src-homology 2–containing inositol phosphatases in chronic idiopathic urticaria Becky M. Vonakis,

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract Sheila M. Amar, MD, Ronald.

Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis Carmen Rondón, MD, PhD, Paloma Campo,

Allergy testing in predicting outcome of open food challenge to peanut

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

IL-5 T-cell responses to house dust mite are associated with the development of allergen-specific IgE responses and asthma in the first 5 years of life

Reply Journal of Allergy and Clinical Immunology

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors Donald W. MacGlashan, MD, PhD,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Decreases in human dendritic cell–dependent TH2-like responses after acute in vivo IgE neutralization John T. Schroeder, PhD, Anja P. Bieneman, BS, Kristin.

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

What is an “eosinophilic phenotype” of asthma?

Skin prick test to egg white provides additional diagnostic utility to serum egg white– specific IgE antibody concentration in children Adina Kay Knight,

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

House dust mite sublingual immunotherapy: Results of a US trial

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Prevention of food allergy: Beyond peanut

Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract Anil Nanda, MD, Maeve O'Connor, MD,

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Oral peanut immunotherapy in children with peanut anaphylaxis

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Nasal challenge with allergen leads to maxillary sinus inflammation

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously Shilpa H. Desai, BS, MD, Akhil Chouksey, MD, John Poll, RN, Melvin Berger,

Päivi M. Salo, PhD, Samuel J. Arbes, DDS, MPH, PhD, Patrick W

Macrolide antibiotics and asthma treatment

The natural history of milk allergy in an observational cohort

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Lisa A. Beck, MD, Sarbjit Saini, MD

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Natural history of cow’s milk allergy

The Editors' Choice Journal of Allergy and Clinical Immunology

Differences in Effects of Omalizumab on Late-Phase Responses to Allergen Challenge in the Skin and Nose at the Time of Basophil Hyporesponsiveness Miya.

Presentation transcript:

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge John A. Eckman, MD, Patricia M. Sterba, MS, Denise Kelly, RN, BSN, Val Alexander, BS, Mark C. Liu, MD, Bruce S. Bochner, MD, Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD Journal of Allergy and Clinical Immunology Volume 125, Issue 4, Pages 889-895.e7 (April 2010) DOI: 10.1016/j.jaci.2009.09.012 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Overall study design. ∗Midstudy NAC and SPTT occurred when cat allergen BHR was <20% of baseline or ∼ day 45. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Cat allergen–induced BHR in omalizumab (n = 12; A) and placebo recipients (n = 4; B) relative to the day of study. All comparisons are within each group relative to relative to the response measured at baseline (day 0) by 2-tailed paired t test. Error bars, SEM. ∗P < .05; ∗∗P < .01; #P < .001; ‡P < .0001. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 The percent of cat allergen–specific IgE to total IgE is correlated to the timing of the midstudy NAC for subjects receiving omalizumab. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Average VAS score in omalizumab-treated (n = 12; A) subjects grouped according to the dose of allergen and NAC visit. Average sneeze counts in omalizumab treated (n = 12; B) and placebo-treated subjects (n = 4; C) grouped according to the dose of allergen and NAC visit. PGD2 levels in nasal lavage for each NAC allergen dose at the 3 NAC time points in actively treated subjects (n = 11; D). Closed circles, Baseline NAC; closed squares, midstudy NAC; open circles, final NAC; error bars, SEM. ∗P < .05; ∗∗P < .01; #P < .001; ‡P < .0001. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Average SPT flare size in omalizumab (n = 12; A) and placebo (n = 4; B)–treated subjects at the time of indicated NAC. Error bars, SEM. ∗P < .05; 2-tailed, paired t test compared with baseline SPT value. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Average VAS score in placebo-treated (n = 4) subjects grouped according to the dose of allergen and NAC visit. Error bars, SEM. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

PGD2 levels in nasal lavage for each NAC allergen dose at the baseline (closed circle) and final (open circle) NAC time points in placebo-treated subjects (n = 3). Error bars, SEM. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Average SPT wheal size in omalizumab-treated (n = 12) subjects at the time of indicated NAC. ∗P < .05; 2-tailed, paired t test compared with baseline SPT value. Error bars, SEM. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Average SPT wheal size in placebo-treated subjects (n = 4) subjects at the time of indicated NAC. Error bars, SEM. Journal of Allergy and Clinical Immunology 2010 125, 889-895.e7DOI: (10.1016/j.jaci.2009.09.012) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions